GLP-1 & Incretin Science

What Is Tirzepatide? The First Dual Incretin Agonist

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Tirzepatide is a 39-residue synthetic peptide that activates both the GIP and GLP-1 receptors from a single molecule, the first dual incretin agonist to reach the market. Built on a modified GIP backbone with a C20 fatty diacid for weekly dosing, it reported up to 22.5% weight reduction over 72 weeks in SURMOUNT-1.

Key facts

Class
Dual GIP / GLP-1 receptor agonist
Developer
Eli Lilly
Residues
39 amino acids
Molecular weight
~4,813 Da
Molecular formula
C225H348N48O68
PubChem CID
156588324
Backbone
Modified GIP scaffold
Brands
Mounjaro, Zepbound

Why a GIP backbone rather than a GLP-1 one

This is the design decision that defines tirzepatide. Rather than starting from GLP-1 and adding GIP activity, Lilly started from GIP and engineered in GLP-1 receptor binding. The resulting molecule is a full GIP receptor agonist with somewhat weaker GLP-1 activity relative to native GLP-1: an imbalanced dual agonist by design, not an evenly split one. Retatrutide later used the same GIP-scaffold strategy to add a third receptor.

What GIP adds

Glucose-dependent insulinotropic polypeptide is the other major incretin hormone, and it accounts for a substantial share of the incretin effect in healthy physiology. Its contribution to weight reduction is still debated. GIP receptor agonism and antagonism have both been argued to help, which is an unusual state for a field to be in. What is not in dispute is the empirical result: adding GIP activity to GLP-1 activity produces more reduction than GLP-1 alone.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

SURMOUNT-1 and the estimand distinction

SURMOUNT-1 ran 72 weeks testing 5 mg, 10 mg and 15 mg once weekly. It is commonly quoted two different ways. On the treatment-regimen estimand, covering everyone randomised, 10 mg produced 19.5% and 15 mg 20.9%. On the efficacy estimand, covering those who adhered, the same arms produced 21.4% and 22.5%. Both sets appear in the literature; the higher pair is quoted far more often. Published in the New England Journal of Medicine in June 2022.

Head to head against semaglutide

SURMOUNT-5 randomised 751 adults with obesity and without type 2 diabetes to maximum tolerated tirzepatide (10 or 15 mg) or maximum tolerated semaglutide (1.7 or 2.4 mg) for 72 weeks. Tirzepatide produced 20.2% mean reduction against semaglutide's 13.7%, and 18.4 cm waist reduction against 13.0 cm, both significant at p<0.001. Gastrointestinal adverse events causing discontinuation were lower on tirzepatide at 2.7% than semaglutide at 5.6%.

Where it sits in the landscape

Tirzepatide is currently the most effective incretin with a marketing authorisation. Compounds reporting larger figures (retatrutide at 28.3%, CagriSema at 22.7%) are investigational or under review. It is marketed as Mounjaro for type 2 diabetes and Zepbound for weight management.

Frequently asked questions

Is tirzepatide a GLP-1 drug?

It is more than one. Tirzepatide activates both the GIP and GLP-1 receptors, which is why it is described as a dual agonist rather than a GLP-1 agonist.

Why is SURMOUNT-1 quoted as both 20.9% and 22.5%?

Different estimands. 20.9% covers everyone randomised on 15 mg; 22.5% covers those who adhered to treatment.

Is tirzepatide better than semaglutide?

On weight reduction, SURMOUNT-5 showed a clear head-to-head advantage: 20.2% against 13.7% at 72 weeks. Semaglutide has the larger cardiovascular outcome evidence base.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.